Peritia Unifies Brands to Streamline Life Sciences Development

MORRISVILLE, NC – January 28, 2026 – In a strategic move aimed at simplifying the complex path from laboratory concept to market reality, life sciences consulting firm BioBridges has formally rebranded, consolidating its legacy brands into a single, integrated entity named Peritia. The announcement signals the evolution of a collection of specialized service providers into a unified platform designed to support the entire life sciences product journey.

The new brand, Peritia, now encompasses the capabilities of BioBridges, health economics and outcomes research (HEOR) specialist CHEORS, and clinical monitoring network Monitorforhire. This integration aims to provide biotech, pharmaceutical, and medtech companies with a seamless, end-to-end partner, moving away from the fragmented vendor landscape that often complicates product development.

A Strategic Consolidation for a Complex Industry

The decision to unify under a single banner is a direct response to the mounting pressures on life sciences organizations, which are increasingly tasked with accelerating innovation while navigating resource constraints. By merging distinct but complementary services, Peritia positions itself as a comprehensive solution for companies that need a partner capable of seeing the full picture, not just a single functional slice.

The legacy brands each brought a critical piece to the new, integrated puzzle:
* BioBridges, founded in 2005, built a strong reputation for providing highly skilled experts for clinical development, regulatory affairs, and quality assurance.
* CHEORS, which joined the fold in 2024, contributed deep expertise in Health Economics and Outcomes Research (HEOR), a crucial component for demonstrating a product's value and securing market access.
* Monitorforhire, also acquired in 2024, provided a robust network of independent clinical research monitors, enabling companies to scale their trial operations efficiently.

Under the new structure, these capabilities are organized into three core pillars—Science, Strategy, and Solutions—reflecting the complete product lifecycle. This framework is designed to offer clients cohesive support that spans corporate and product strategy, operational execution, and the critical final stages of demonstrating value, evidence, and access.

Redefining the Partner Model in Life Sciences

The life sciences service sector is a competitive field, with large players like IQVIA and Syneos Health offering a wide array of services. Peritia aims to differentiate itself not just by the breadth of its offerings, but by the depth of their integration. The company's leadership believes that a truly unified operating philosophy can eliminate the silos that often slow down progress.

"Launching as Peritia reflects how life sciences companies actually work—integrating science, strategy, and execution to move faster and more confidently," said Mark Bouck, CEO and Chairman of the Board at Peritia, in a statement. "Under one unified brand, our team members can collaborate more seamlessly across disciplines to help clients accelerate development timelines and achieve impactful results."

This approach directly addresses a growing market demand for holistic solutions. Industry analysis indicates a clear shift away from using multiple "point solutions" towards adopting integrated platforms that can tackle challenges like data fragmentation, operational inefficiencies, and complex supplier networks. For many pharma and biotech firms, the appeal of a single, accountable partner that can manage the journey from discovery to delivery is a powerful proposition for improving efficiency and maintaining compliance.

The 'Peritia' Promise: Practical Expertise in Action

The choice of the new name is itself a statement of intent. As Bouck noted, "Peritia" is Latin for "practical knowledge, experience, and expertise." This branding underscores the company's focus on delivering tangible, outcome-driven results rather than purely theoretical advice. The firm promises to translate its deep scientific and strategic insights into actionable solutions that keep development programs on track.

This philosophy of adaptability is central to the company's value proposition. "Life sciences innovation rarely follows a straight line, so our approach is intentionally adaptable," added Jennifer Thayer, Chief Strategy Officer. "Whether a client needs support refining a clinical development strategy, selecting an indication, scaling clinical operations, or building an evidence package for access and reimbursement, our goal is to deliver practical, flexible, and high-quality solutions to keep programs moving forward."

While the Peritia brand is new, the expertise behind it is well-established. The combined entities have a history of serving over 700 clients across more than 80 countries, completing over 4,000 successful engagements. This extensive track record provides a foundation of trust and proven capability that the new platform will build upon.

Leadership and Vision for Future Growth

The formation of Peritia is the culmination of a deliberate, multi-year strategy driven by its leadership and private equity backers. CEO Mark Bouck was brought in by Waud Capital Partners to lead PharmAlliance, the platform that made its initial investment in BioBridges in 2023. Bouck, with a significant background in growing and scaling pharmaceutical service companies, including as the former CEO of TrialCard, was tasked with building a leading business in the fragmented pharma services market through both organic growth and strategic acquisitions.

The subsequent acquisitions of Monitorforhire and CHEORS in 2024 were not coincidental but were calculated moves to round out the platform's capabilities in response to market and client needs. This methodical expansion demonstrates a clear vision to construct a full-service provider capable of addressing every major stage of the commercialization pathway. This long-term strategy, now realized under the Peritia brand, suggests a deep understanding of the industry's trajectory and a commitment to evolving alongside it.

As the life sciences industry continues its rapid transformation, driven by digital innovation and scientific breakthroughs, the need for agile and comprehensive partners is greater than ever. The launch of Peritia as a unified brand marks a significant step in building a next-generation life sciences partner grounded in scientific rigor and tailored, practical solutions. The company has stated its intent to continue investing in expanding its capabilities and service lines to help organizations adapt, advance, and lead with confidence across the full product lifecycle.